Prices of 137 life-saving cancer medicines came down from Monday following a move by National Pharmaceutical Pricing Authority (NPPA) to cap trade margins at 30%. The decision follows a Supreme Court hearing in late Sept on the high cost of cancer treatment, during which an example was cited of a cancer drug bought by a shop for ₹2,700 being sold to patients for ₹27,000, a tenfold increase.